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Chapter 1 – Abstract
Chapter 1
Abstract
Previous studies have proven the antidiabetic properties of Artemisia dracunculus L.  
through various approaches. In the face of the present diabetes epidemic, looking 
into new approaches and developing remedies that differ from the traditional forms 
of treatment is pivotal. Testing extracts of  Artemisa dracunculus,  a plant that has 
safely been applied in traditional medicine, thus seems very promising.   
In this study, a rat model was used to evaluate the effects of A. dracunculus extracts 
not only on blood glucose levels, but on dipeptidyl peptidase IV (DPPIV) levels and 
plasma insulin  as  well,  employing DPPIV assay and insulin  ELISA respectively. 
Results of basal and glucose tolerance tests were evaluated. By conducting a dose 
finding study, the extract concentration of 60mg/kg could be identified as being most 
effective in lowering blood glucose levels und therefore most  suitable for further 
testing.
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Abstract
In  früheren  Studien  wurden  die  antidiabetischen  Eigenschaften  von  Artemisia 
dracunculus  L.  bereits  mittels  verschiedener  Herangehensweisen  nachgewiesen. 
Angesichts  der  gegenwärtigen Diabetes-Epidemie  ist  es  unabdingbar, nach neuen 
Herangehensweisen  zu  suchen,  um  Arzneimittel  zu  entwickeln,  die  von 
traditionellen  Heilmethoden  abweichen.  Die  Untersuchung  von  Extrakten  von 
Artemisia dracunculus  L.,  einer Pflanze,  die in der  traditionellen Medizin bereits 
angewendet wurde, erscheint daher vielversprechend.
In der vorliegenden Studie wurde ein Rattenmodel für die Untersuchung der Effekte 
von  A.  dracunculus–Extrakten  nicht  nur  auf  Blutzuckerwerte,  sondern  auch  zur 
Klärung  des  möglichen  Wirkmechanismus  durchgeführt.  Hierzu  wurden 
Dipeptidylpeptidase  IV  (DPPIV)  assays  beziehungsweise  Insulin  ELISA 
angewendet. Mittels einer Dosisfindungskurve konnte die Extraktkonzentration von 
60  mg/kg  als  diejenige  identifiziert  werden,  die  Blutzuckerwerte  am effektivsten 
senkte und daher für weitere Tests am besten geeignet war. 
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Chapter 2
Objectives and Introduction
Tarragon (Artemisia dracunculus L.) of the family  Asteraceae, is a perennial herb 
with a long history of medical and culinary use. While in traditional medicine mainly 
used as a remedy for gastrointestinal disorders, recent studies looked into possible 
antidiabetic and glucose-lowering effects of A. dracunculus ([Ribnicky et al., 2009], 
[Govorko et al., 2007], [Logendra et al., 2006], [Wang et al., 2008]). Several active 
compounds  have  already  been  identified:  polyphenoles  such  as   6-
demethoxycapillarisin,  2',4'-dihydroxy-4-methoxydihydochalcone  and  4,5-di-O-
caffeoylquinic  acid,  flavonoids  such  as  luteolin  and  apigenin,  the  coumarin 
scopoletin  and  the  sesquiterpenoid  lactone  costunolide  as  well  as  cinnamates 
([Govorko et al, 2007], [Logendra et al., 2006], [Duke, 1992], [Huang et al., 1993], 
[Arlt  et  al.,  2004],  [Liu  et  al.,  2003]).  In  2001,  the  German  'Bundesinstitut  für 
gesundheitlichen Verbraucherschutz und Veterinärmedizin' released a statement  in 
which the hepatocarcinogenic effects of estragole and methyleugenol were described 
– compounds that can also be found in  A. dracunculus and its ethanolic extracts, 
while  water  extracts  contain  no  detectable  amounts  of  those  components  (Data 
courtesy of Finzelberg GmbH &Co KG). 
In order to assess the effect of  A. dracunculus extracts on blood glucose, plasma 
insulin  levels  and  DPPIV  activity, a  standard  animal  model  for  the  testing  of 
antidiabetic activity was used. Based on literature such as Verspohls "Recommended 
testing in diabetes research'' (2002), it was chosen to work with a rat model, with 
blood collection from the vena sublingualis.
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The specific objectives of the present work consists of:
1.  Conducting a dose finding study to identify the most active concentration of  
     extract
2.  To get hints on the possible mechanism of action by measuring insulin plasma   
     levels and DPPIV enzyme activity.
The following chapter gives insight into the metabolic disease diabetes and current 
treatment options, draws an outline of the prevalence of diabetes in our society and 
gives an outlook into the future. Chapter 4 provides a detailed description of the 
plant A. dracunculus, its compounds and traditional use and presents previous studies 
dealing  with  its  antidiabetic  properties.  Materials  and  methods  are  discussed  in 
chapter 5. Results are presented and debated in chapters 6 and 7.
12
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Chapter 3
Diabetes 
1. Introduction
Diabetes mellitus is a metabolic disorder with elevated blood glucose levels, caused 
by  inadequate  insulin  secretion,  as  its  main  clinical  symptom.  Based  on  the 
pathologic processes that lead to hyperglycemia and disordered metabolism, diabetes 
mellitus can be classified into two main groups ([Kasper, Harrison, 2005], [McPhee, 
Papadakis, 2008]).
1.1. Diabetes mellitus type 1
Type 1 diabetes or insulin dependent diabetes, is caused by a combination of genetic, 
environmental  and  immunological  elements  that  eventually  lead  to  autoimmune 
distruction of pancreatic beta cells and severe or absolute insulin deficiency. Over 
90%  of  cases  are  immune-mediated,  less  than  10%  are  idiopathic.  Altough 
environmental factors are believed to play a major part in the development of type 1 
diabetes,  the  causes  for  the  autoimmune injuries  are  still  unknown,  but  different 
hypotheses, such as infections with viruses (e.g. rubella, coxsackie B4), have been 
discussed.  Therapy  of  patients  with  diabetes  type  1  consists  in  lifelong 
supplementation of  insulin  ([Kasper,  Harrison,  2005],  [McPhee,  Papadakis,  2008] 
[Katzung, 2007]).
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1.2. Diabetes mellitus type 2
Type 2  diabetes,  also  known  as  non-insulin  dependent  diabetes  or  adult-onset 
diabetes,  is  defined  as  a  group  of  syndromes  characterized  by  the  presence  of 
hyperglycemia, which is caused by a progressive loss of  beta-cell function as the 
central  feature.  ([McPhee,  2005],  [The  Expert  Committee  on  the  Diagnosis  and 
Classification of Diabetes Mellitus, 2003], [McPhee, Papadakis, 2008]). 
In addition to insulin resistance, individuals with type 2 diabetes mellitus suffer from 
impaired insulin secretion and show a characteristic decrease in the early release of 
insulin, also known as first-phase insulin release, all of which results in deficient 
insulin action. The dominating malfunction varies, ranging from insulin resistance 
with  relative  insulin  deficiency  to  a  predominating insulin  secretory  defect  with 
insulin  resistance  ([Kasper,  Harrison,  2005],  [The  Expert  Committee  on  the 
Diagnosis and Classification of Diabetes Mellitus, 2003]). 
The molecular or genetic defects responsible for the development of type 2 diabetes 
mellitus are for the most part still unclear, but it can be assumed that a combination 
of  polygenetic  origins  and environmental  factors,  such as  an unhealthy diet  or a 
sedentary  lifestyle,  lead  to  both  insulin  resistance  and  beta  cell  loss  ([McPhee, 
Papadakis, 2008], [McPhee, 2005]).
The  following  quote  describes  very  well  the  different risk  factors  of  developing 
diabtes:
„The risk of developing type 2 DM increases with age, obesity and lack of  
physical activity. It occurs more frequently in women with prior gestational 
diabetes mellitus and in individuals with hypertension or dyslipidema, and its  
frequency varies in different racial/ethnic subgroups.“ 
(Source:  The  Expert  Committee  on  the  Diagnosis  and  Classification  of  
Diabetes Mellitus, 2003)
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80% of patients presenting with diabetes mellitus (DM) also suffer from obesity, 
notably  in  central  or  visceral  location,  which increases insulin  resistance.  Insulin 
resistance in early and prediabetic stages is compensated by hyperplasia in beta cells 
([Kasper, Harrison, 2005], [McPhee, 2005]). This correlates with the fact that factors 
such  as  increased  body-mass  index,  heightened  liver-enzyme  levels,  smoking, 
reduced insulin secretion and a corresponding family history are the main prognostic 
symptoms (Lyssenko et al., 2008). 
Before  type  2  DM  becomes  manifest,  it  is  preceded  by  abnormal  glucose 
homeostasis, a condition known as impaired glucose tolerance (IGT) and impaired 
fasting glucose (IFG). This stage is also referred to as prediabetes.  At this point, 
lifestyle modification and the prescription of oral antidiabetic agents can delay or in 
some cases even prevent the onset of DM, as prediabetes is considered rather a risk 
factor  for  the development of  diabetes  and cardiovascular disease than a  clinical 
entity,  altough  it  is  associated  with  the  insulin  resistance  syndrome  ([Kasper, 
Harrison,  2005],  [The  Expert  Committee  on  the  Diagnosis  and  Classification  of 
Diabetes Mellitus, 2003] [Rosenstock, 2007]). Screening for prediabetes is advisable 
in people older than 45 as well as in adults below the age of 45 if aforementioned 
risk factors are present (Crandall et al., 2008).
2. The diabetes epidemic
Diabetes is one of the most common non-communicable diseases globally, with type 
2 diabetes constituting about 85% to 95% of all cases in developed countries. Being 
the fourth to fifth leading cause of death in most developed countries and a prime 
cause  of  excess  cardiovascular  morbidity  and  mortality  in  Western populations, 
diabetes is epidemic in many developing and newly industrialized nations and can be 
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considered one of the main threats to human health in the 21st century. ([Zimmet et  
al., 2001], [Allgot, Gan, et al., 2003][Reimann et al., 2009]).
Figure 1. The prevalence of diabetes in 2000 and the projected prevalence in 2030.
The prevalence of diabetes globally is estimated to rise from 171 million in 2000 to 
366 million in 2030, which is an enormous increase from 2.8% to 4.4% in 2030 (see 
Figure 1). 
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Figure 2 illustrates the 46% increase in diabetes cases worldwide from 2000 to 2010 
(Zimmet et al., 2001). These figures are based on the assumption that the prevalence 
of  obesity  remains  stable.  As  this  seems  highly  unlikely,  and  taking  into 
consideration that the number of individuals with IGT, also termed prediabetes, may 
be equal or even higher than that of people with diabetes, the total of diabetes cases 
in 2030 could be considerably higher ([Wild et al., 2004], [Goodman, Gilman 2006], 
[Ryan, Espeland et al., 2003]). 
Figure 2. Numbers of people with diabetes (in millions) for 2000 and 2010 (top and 
     middle values respectively), and the percentage increase 
     (Source: Zimmet et al., 2001)
The human and economic costs societies all over the world will subsequently have to 
face will be enormous, not only due to the numerous asocciated illnesses, but also 
due to the incremental costs of diabetes, beginning at least eight years prior to the 
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diagnosis  ([Wild  et  al.,  2004],  [Logendra  et  al.,  2006],  [Nichols  et  al.,  2000], 
[Stummvoll  et  al.,  2005]).  Due to the residual  insulin secretion and the fact that 
hyperglycemia  develops  gradually,  patients  are  often  asymptomatic  and  remain 
undiagnosed for a considerable time ([McPhee, 2005], [The Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus, 2003]). 
In  this  regard,  early  discovery  of  diabetes  and  delaying  its  progress  is  pivotal 
(Reimann  et  al.,  2009).  The  numerous  complications  that  develop  in  long-term 
diabetes patients, such as retinopathy with potential loss of vision, nephropathy and 
subsequent  renal  failure,  peripheral  neuropathy  and  foot  ulcers,  autonomic 
neuropathy causing gastrointestinal, genitourinary and cardiovascular symptoms and 
sexual dysfunction all account for the rising health care costs for diabetes-related 
diseases ([The Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus, 2003]).
Alternative  strategies  like  nutritional  supplementation  with  botanical  agents  in 
addition to the traditional strategy of reducing food intake and increasing physical 
activity could be essential ([Zuberi, 2008], [Wang et al. 2008]).  
This  is  particularly  important,  as  conventional  treatments  such  as  insulin  and 
sulfonylureas have been proven to produce weight gain and could thus eventually 
exacerbate the disease (UK Prospective Diabetes Study group 1998).  Plants have 
always been an abundant  source  of  medicinal  compounds,  with numerous plants 
being known for their antidiabetic activity, but there is still  a want of thoroughly 
controlled studies on efficacy and safety in the use of such products ([Wang et al., 
2008], [Ribnicky et al., 2006]).
18
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3. Treatment options
3.1. Hypoglycaemic drugs
When diet and physical activity programs fail to show a significant effect in lowering 
blood glucose levels, oral antidiabetics are required. 
Depending on their mechanism of action, drugs for treating type 2 diabetes mellitus 
fall into several categories: 
(1) Sulfonylureas primarily stimulate insulin secretion by binding to the sulfonylurea 
receptor.  The  meglitinide  analog  repaglinide  and  the  D-phenylalanine  derivate 
nateglinide use the same mode of action.  
(2) Drugs that alter insulin action: while biguanides have their point of action in the 
liver, thiazolidinediones appear to be working in both skeletal muscle and adipose 
tissue. 
(3) α-Glucosidase inhibitors alter insulin action. 
(4) Exenatide and DPPIV inhibitors mimic incretin effect or prolong incretin action.
(5)  Other: Pramlintide suppresses glucagon and slows gastric emptying (McPhee, 
Papadakis, 2008). 
Treatment of patients with type 2 DM must also include taking care of conditions 
associated  with  type  2  DM,  such  as  obesity,  hypertension,  dyslipidemia  and 
cardiovascular diseases,  as well as the management of DM-related complications. 
These are numerous and highly common in patients suffering from type 2 DM, with 
cardiovascular complications being the leading cause of mortality (Kasper, Harrison, 
2005).
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3.1.1. Stimulating insulin secretion 
3.1.1.1. Sulfonylureas
By binding on sulfonylurea receptors on the surface of pancreatic β-cells, efflux of 
potassium ions  through  the  ATP-sensitive potassium channel  is  inhibited,  which 
results in depolarisation and subsequent influx of calcium. This active promotion of 
insulin release is only possible if functioning pancreatic β-cells are present. Acute 
administration  improves  the  early  phase  of  insulin  release,  while  long-term 
administration reduces serum glucagon levels  ([Kasper,  Harrison, 2005], [McPhee, 
Papadakis, 2008]). 
Sulfonylureas  can  be  divided  into  first  generation  (tolbutamide,  tolazamide, 
acetohexamide, chlorprogamide) and second generation drugs (glyburide, glipizide, 
gliclazide, glimepiride). Second generation sulfonylureas show fewer adverse effects 
and drug interactions, as well as a lower incidence of hypoglycemia, but tolbutamide 
is probably the safest sulfonylurea to use both when liver function is normal and for 
elderly diabetics  ([Kasper,  Harrison, 2005], [McPhee, Papadakis, 2008] [Katzung, 
2007]). 
Glyburide (see structure in figure 3) was used as the positive control in this study to 
evaluate the antidiabetic potency of Artemisia dracunculus L. extracts .
Figure 3. Structural formula of glyburide (Created with Symyx Draw 3.3).
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3.1.1.2. Miglitinide and D-Phenylalanine derivative 
Following  the  same  mode  of  action  as  the  sulfonylureas  but  being  rapidly  and 
completely  metabolised,  both  miglitinide  and  nateglinide  cause  a  brief  but  rapid 
pulse  of  insulin.  Main  side  effects  are,  as  with  the  other  insulin  secretagogues, 
hypoglycemia  and  weight  gain  ([Katzung,  2007],  [Goodman,  Gilman,  2006], 
[McPhee, Papadakis, 2008]).
3.1.2. Altering insulin action
3.1.2.1. Biguanides
The main biguanide in use is metformin (see figure 4 below). It is antihyperglycemic, 
not hypoglycemic. Its mechanism of action has not yet been fully explained, but the 
following  effects  have  been  proposed:  a  reduction  of  hepatic  and  renal 
gluconeogenesis, slowing of glucose absorption from the gastrointestinal tract, direct 
stimulation of glucolysis in tissues, thus inducing increased glucose removal from 
blood, and finally a reduction of plasma glucagon levels as well as moderate weight 
loss ([Katzung, 2007], [Goodman, Gilman, 2006], [McPhee, Papadakis, 2008]).
Figure 4. Structural formula of metformin (Created with Symyx Draw 3.3).
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Metformin  is  indicated  for  use  in  combination  with  insulin  secretagogues  or 
thiazolidinediones in patients with type 2 DM with inadequate oral monotherapy, but 
can also be given alone ([Katzung, 2007], [Goodman, Gilman, 2006]. 
3.1.2.2. Thiazolidinediones
Thiazolidinediones sensitize peripheral tissues to insulin. They are selective agonists 
for nuclear peroxisome proliferator-activated receptor γ (PPARγ) which promotes the 
activation  of  insulin-responsive  genes  that  regulate  carbohydrate  and  lipid 
metabolism.  It  has  also  been  observed  that  thiazolidinediones  induce  increased 
expression of glucose transporters GLUT 1 and GLUT 4, decrease free fatty acid 
levels  and  glucose  production in  the liver  ([Katzung,  2007],  [Goodman,  Gilman, 
2006], [McPhee, Papadakis, 2008]).
Figure 5.  Structural formula of the thiazolidinediones rosiglitazone and    
     pioglitazone (Created with Symyx Draw 3.3).
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Currently available drugs of this class are pioglitazone and rosiglitazone (see figure 5 
for structural formula). They can be used either as monotherapy or in combination 
with  sulfonylureas,  metformin  or  insulin.  The  combined  application  of  a 
thiazolidinedione  and  metformin  has  the  advantage  of  not  causing hypoglycemia 
([Katzung, 2007], [Goodman, Gilman, 2006]). 
Adverse effects: thiazolidinediones have been reported to cause anemia, weight gain, 
edema  and  plasma  volume  extension.  Additionally,  liver  function  should  be 
monitored (Katzung, 2007).
3.1.3. Affecting glucose absorption – α-Glucosidase inhibitors
α-Glucosidase  inhibitors  competively  inhibit  the  α-glucosidase  enzymes,  which 
delays the absorption of carbohydrates and reduces intestinal absorption of starch, 
dextrin and disaccharides. Both currently for clinical use available drugs – acarbose 
and miglitol – are potent inhibitors of glucoamylase, α-amylase and sucrease. The 
fundamental difference between the two drugs is their absorption. Acarbose, having 
sturctural  features of a  tetrasaccharide, is absorbed only to a small degree, while 
miglitol has a structural similarity with glucose and is absorbable. 
α-Glucosidase  inhibitors  are  typically  used  in  combination  with  other  oral 
antidiabetic agents or insulin. 
Adverse effects: the most common adverse effect in both acarbose and miglitol is 
flatulence, followed by diarrhea and abdominal pain. All of these symptoms stem 
from  the  appearance  of  undigested  carbohydrate  in  the  colon  ([Katzung,  2007], 
[Goodman, Gilman, 2006], [McPhee, Papadakis, 2008]).
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3.1.4. Mimicking incretin effect or prolonging incretin action – exenatide and   
dipeptidyl peptidase IV inhibitors
DDPIV inhibitors are the newest class of oral antidiabetics.
The  two  gut  hormones  glucagon-dependent  insulinotropic  polypeptide  (GIP)  and 
glucagon-like peptide (GLP-1) are also known as incretins. The secretion of GLP-1, 
which enhances insulin release and lowers glucose levels, is reduced in patients with 
type 2 DM. It also suppresses glucagon secretion and thus improves postprandial 
hyperglycemia.  It  additionally  delays  gastric  emptying  and  decreases  appetite 
([McPhee, Papadakis, 2008], [Barnett, 2006]). 
GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase IV (DPPIV), which 
would make continuous infusion necessary for obtaining a clinical effect. Exenatide 
is a GLP-1 receptor agonist that is more resistant to DPPIV and has the same effects 
on  glucagon  supppression  and  gastric  emptying  as  GLP-1 (McPhee,  Papadakis, 
2008).
Another approach is the application of the latest class of oral antidiabetic agents: 
DPPIV  inhibitors  such  as  sitagliptin  (see  figure  6)  prolong  the  action  of 
endogenously released GLP-1 and GIP and have been shown to effectively lower 
glucose  when  used  alone  or  in  combination  with  metformin  and  pioglitazone 
([Goodman, Gilman, 2006], [McPhee, Papadakis, 2008], [Katzung, 2007], [Green et 
al., 2006], [Geelhoed-Duijvestijn, 2007]). Additionally, preclinical data suggests that 
DPPIV inhibitors may also preserve beta cell function and increase beta cell mass 
(Mu et al., 2006).
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Figure 6. Structural formula of the DPPIV inhibitor sitagliptin (Created with Symyx 
     Draw 3.3).
3.1.5. Other – Pramlintide
Pramlintide is a synthetic analogon of amylin, a peptide produced in pancreatic beta 
cells.  It  is  cosecreted with insulin  and inhibits  glucagon secretion,  delays gastric 
emptying and suppresses appetite. The drug is administered subcutanously and in 
addition  to  insulin.  Major  side  effects include  hypoglycemia  and  gastrointestinal 
symptoms such as nausea, vomiting and anorexia (Katzung, 2007).
3.2. Insulin
Due to the progressive nature of type 2 DM and the relative insulin deficiency that 
develops  eventually, a  considerable  number  of  patients  ultimately  require  insulin 
therapy (Kasper, Harrison, 2005). Insulin is injected subcutaneously and diffuses into 
the peripheral circulation.  
Commercially available preparations of insulin can be classified according to their 
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duration of action into short, intermediate and long acting, and by their species of 
origin as human or porcine (Goodman, Gilman, 2006). 
3.2.1. Unitage
For  therapeutic  purposes,  doses  and  concentrations  of  insulin  are  expressed  in 
international units (IU), ensuring that different preparations with the same biological 
effect  contain  the  same  number  of  IUs.  Following  the  guidelines  of  the  Expert 
Committee on Biological Standardization of the World Health Organisation, one IU 
insulin is the biological equivalent of about 45.5 µg pure crystalline insulin (1/22mg 
exactly). This is the amount of insulin required to reduce the concentration of blood 
glcose in a fasting rabbit to 45mg/dl (2.5mM).
3.2.2. Classification of insulins
As mentioned above, insulin preparations can be divided, according to their time of 
onset  and duration of  their  biologic  action.  Rapidly/short  acting insulins  such as 
insulin lispro, insulin aspart  and insulin glulisine are administered before a meal, 
while  long  acting,  „peakless“  insulin  formulations  such  as  insulin  glargine  and 
insulin  detemir  are  given  to  create  a  stable  basal  coverage.  Neutral  Protamine 
Hagedorn  (NPH)  insulin  is  an  intermediate  acting  preparation.  There  also  exist 
special insulin formulations that can be delivered by inhalation, are absorbed quickly 
and show a rapid onset of action ([Goodman, Gilman, 2006], [McPhee, Papadakis, 
2008]).
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Chapter 4
Artemisia dracunculus L.
1. Botany and Phytochemistry
The  genus  Artemisia,  which  is  part  of  the  family  of  composites  (Asteraceae), 
comprises about 500 plants, most of which are perennials native to Europe, Russia, 
Mongolia,  China  and  western  and  central  North  America.  ([Jung  et  al.,  2007], 
[Franke, Lieberei, 1997], [Hoppe, 1975]).
Figure 7. Artemisia dracunculus L.
    (Source: http://plants.usda.gov/gallery/standard/ardr5_001_svd.jpg)
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Of  the  species Artemsisia  dracunculus  L.,  commonly  known  as  tarragon,  two 
varieties  exist.  French  tarragon  (Artemisia  dracunculus  var. sativa),  a  popular 
seasoning, is known to be more aromatic and reproduces only vegetatively. Russian 
tarragon (Artemisia dracunculus var. inodora),  has a more acrid taste and can be 
grown from seed. It is more sturdy and can reach a hight of about 150 cm. The 
yellow or greenish-white flowers are small capitulae of about 2 – 4 mm in diameter 
that contain up to 40 florets. ([Dachler, Pelzmann, 1999], [Franke, Lieberei, 1997]). 
The  long  and  smooth  leaves  contain  the  greatest  amount  of  volatile  oil.  French 
tarragon contains 0.15 – 3.0% essential oil, estragol (methylchavicol) being the main 
constituent with 68 – 80%, as well as various amounts of cis- and trans-ocimene and 
limonene. The oil has an anisseed-like taste. Russian tarragon yields 0.25 – 2.0% 
essential  oil.  The  prinicpal  constituents  are  sabinene,  elemicine  and  trans-
isoelemicin, resulting in a bitter chervil-like taste of the oil [Wright, C., 2002)].
The extracts used for the present study were obtained from Artemisia dracunculus 
var. inodora. 
2. Traditional and modern use 
2.1. Background 
Artemisia  dracunculus is  a  perennial  herb  with  a  long  history  of  medicinal  and 
culinary  use  ([Swanston-Flatt  et  al.,  1991],  [Wang  et  al.,  2008]).  In  traditional 
medicine, aerial parts of the plant are applied to cure various digestive complaints 
(Wright, C., 2002).
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The drug of  A. dracunculus is  Herba dracunculi, the dried aerial part of the plant. 
The main component is the essential oil, Oleum dracunculi (Hoppe, 1975).
The genus Artemisia is not new in diabetes research: Artemisia herba alba has been 
used in Iraqi folk medicine for the treatment of diabetes mellitus, and several studies 
indicating its hypogoglycemic activity have already been completed ([Twaij, H. A., 
Al-Badr, A. A., 1988], [al-Khazraji et al. 1993], [al-Shamaony et al., 1994]). 
The hypoglycemic potency of Artemisia sphaerocephala Krasch and the anti-diabetic 
effect of Artemisia princeps Pampanini extracts have already been proven in animal 
models ([Zhang et al., 2006], [Jung et al., 2007], [Kang et al., 2008]). 
Previous  studies  indicate  that  extracts  of  Artemisia  dracunculus  L. have 
antihyperglycaemic activity and could be of use in the managment of diabetic states, 
suggesting multiple modes of action for the tested extract ([Ribnicky  et al., 2006], 
[Govorko et al., 2007]). A. dracunculus is also being tested for its potential beneficial 
effect on the metabolic syndrome, an illness that is associated with insulin resistance 
(Cefalu et al., 2008).
2.2 Mechanism of action
Artemisia dracunculus L. has been found to have several distinct methods of action 
valuable for the treatmet of diabetes and the complications associated with it:
Ethanolic extracts of A. dracunculus L. were found to be active in insulin-deficient 
(genetically diabetic  KK-Aγ)  mice,  suggesting an insulin-like effect on peripheral 
tissues  and  enhanced GLP-1  receptor  binding  as  probable  mechanisms of  action 
(Ribnicky  et  al.,  2006).  Furthermore,  it  has  been  shown  that  two  polyphenolic 
compounds isolated from A. dracunculus (see below) have an insulin-like effect on 
phosphoenolpyruvate  carboxykinase  (PEPCK)  gene  expression  (Govorko  et  al., 
2007). PEPCK is an enzyme of the metabolic pathway that controls the reversible, 
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rate controlling step of gluconeogesis. It is inhibited by insulin.
Likewise, three compounds of the ethanolic extract proved to inhibit aldose reductase 
(ALR2), an enzyme of the polyol pathway that catalyzes the conversion of blood 
glucose into sorbitol in the presence of NADPH (Logendra et al., 2006).
Figure 8. Artemisia dracunculus L.
     (Source: http://plants.usda.gov/gallery/standard/ardr5_1v.jpg)
In vivo tests with an alcoholic extract, using primary human skeletal muscle cultures 
showed enhanced insulin activity through reduction of phosphatase acitivities such as 
protein tyrosine phosphatase1-B (Wang et al., 2008). 
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2.3. Active compounds
Some compounds of A. dracunculus L. that are responsible for the methods of action 
described  above  have  already  been  identified.  These  compounds  include 
polyphenoles  such  as  6-demethoxycapillarisin,  2',4'-dihydroxy-4-
methoxydihydochalcone and  4,5-di-O-caffeoylquinic acid  ([Govorko  et  al,  2007], 
[Logendra  et  al.,  2006]).  Additionally, other  compounds of  the  aerial  part  of  A. 
dracunculus have already been reported to display antidiabetic activity. This includes 
flavonoids,  such  as  luteolin  and  apigenin,  coumarins  such  as  scopoletin,  and 
sesquiterpenoid lactones such as costunolide, and cinnamates ([Duke, 1992], [Huang 
et al., 1993], [Arlt et al., 2004], [Liu et al., 2003]). 
3. Toxicity
Concerning the possible toxicity of  Artemisia dracunculus L. extracts, inconsisting 
data was published lately. In a recent study, the ethanolic extract of the shots of  A. 
dracunculus showed no noteworthy signs of toxicity and appeared to be safe and 
nontoxic (Cefalu et al., 2008). But in two statements by the German 'Bundesinstitut 
für gesundheitlichen Verbraucherschutz und Veterinärmedizin' (BgVV), released on 
May 11th 2001 and November 12th 2001 respectively, it was advised to reduce the 
intake of products containing estragole and methyleugenol – oraganic compounds 
that can be found in plants like tarragon, basil and anis (see figures 9 and 10). This 
was  substantiated  by  in  vivo experiments  with  rats  and  mice  in  which  those 
compounds proved to be hepatocarcinogenic ([BgVV, may 2001][BgVV, november 
2001]).
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Figure 9. Chemical structure of estragole (Created with Symyx Draw 3.3).
Figure 10. Chemical structure of methyleugenol (Created with Symyx Draw 3.3).
This study has however been subject to criticism for various reasons. The pivotal 
points of criticism concern the fact that monosubstances in concentrations as high as 
1000 mg / kg bodyweight were applied, thus not accounting for the antioxidative 
properties  of  the  multicomponent  mixtures  of  plant  extracts  or  the  possibility  of 
transfering data from the animal study to the human situation ([Iten, Saller, 2004], 
[Smith et al., 2002]).  
The „European Agency for the Evaluation of Medicinal Products“ (EMEA) has since 
issued a reevaluation of herbal medicinal products containing estragole, in  which 
they are deemed to not pose a significant cancer risk if consumed in appropriate 
quantities.  Nonetheless,  exposure  levels  of  estragole  to  sensitive  groups  such  as 
children, pregnant and breastfeeding women should be minimised (European Agency 
for the Evaluation of Medicinal Products, 2004).
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4. Choice of extract
4.1. Extraction method
In order to reduce the amount of estragole and methyleugenol in the extract used in 
this  study, ethanolic  and  water  extracts  were  compared  previously  regarding  the 
content  of those critical  compounds.  It  could be shown that  while water extracts 
contained  no  detectable  ('n.nw'  for  'nicht  nachweisbar'  in  figure  11) amounts  of 
estragole and methyleugenol, this was not true for ethanolic extracts. 
Figure 11.  Content of estragole and methyleugenol in water and ethanolic extracts 
         (Courtesy of Finzelberg GmbH & Co KG, Andernach, Germany)
Extracts  of  French  Tarragon  contained  higher  levels  of  the  aforementioned 
compounds than Russian Tarragon.
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4.2.  Previous studies – choice of subspecies
Studies with Artemisia dracunculus have already been accomplished in Dr. Veronika 
Butterweck's group at the University of Florida prior to the present work. The aim 
was to compare the antidiabetic properties of the subspecies Artemisia dracunculus 
var. sativa (French  Tarragon) and  Artemisia  dracunculus  var. inodora (Russian 
Tarragon). It  could be shown that  Russian Tarragon showed antidiabetic activity, 
with  the  ethanolic  fraction  being  more  active  than  the  aqueous  fraction;  French 
Tarragon was not active (see Figure 12).
Figure 12. Comparison of Russian and French Tarragon in glucose tolerance test
       (Butterweck et al., unpublished)
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It was therefore decided to work with the extract that had the highest antidiabetic 
activity and at the same time the lowest levels of estragole and methyleugenol. As a 
consequence,  the  aqueous  extract  of  Russian  tarragon  was  chosen  for  further 
research.
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Chapter 5
Materials and Methods
1. Materials
1.1. Chemicals, drugs
The volatile anaesthetic isoflurane was purchased at  Webster Veterinary, Sterling, 
Massachusetts,  USA. Halothane and glyburide (glibenclamide) were bought  from 
Sigma-Aldrich,  St.  Louis,  Missouri,  USA.  For  the  second  positive  control  with 
sitagliptin,  Januvia 100  mg,  90  tablets  from  Merck  &  Co.,  Inc.,  Whitehouse 
Station, New Jersey, USA were purchased. The sodium hydroxide used to prepare 
isotonic saline for intraperetoneal injection as well as propylene glycol were obtained 
from Thermo Fisher Scientific, Pittsburgh, Pennsylvenia. USA.
To achieve optimal results, all suspensions were homogenized, using the Power Gen 
125  from  Fisher  Scientific  (Catalogue  No.  14-261-02).  Blood  samples  were 
centrifugated with Eppendorf Centrifuge 5810 R. 
1. 2. Extracts
Different extracts of  Artemisia dracunculus var. inodora were used as provided by 
Finzelberg GmbH & Co KG, Andernach, Germany. The extracts were weighed in 
plastic tubes and diluted with a 0.5% propylene glycol (PG) solution. All dilutions 
were homogenized with the Power Gen 125. 
                                                                                                                                                    
36
Chapter 5 – Materials and Methods
__________________________________________________________________________
1. 3. Control and positive control
Animals received a 0.5% PG solution as control. For this, a stock solution of 0.5 ml 
PG and 99.5 ml purified water was prepared.
Two oral  antidiabetics,  glyburide  and  sitagliptin, were  used  as  positive  controls. 
Suspensions were prepared as follows:
Glyburide was suspended in 0.5% PG solution. Rats received 18 mg/kg glyburide, 
which equals a drug concentration of 3,6 mg/ml.
Sitagliptin  tablets  were  pulverized  with  the  aid  of  a  mortar  and  subsequently 
suspended in 0.5% PG solution. 100 mg/kg sitagliptin were orally administered. The 
durg solution had a concentration of 20 mg/ml.
2. Methods
2.1 Animal Procedures
All animal procedures have been approved and monitored by the Institutional Animal 
Care and Use Committee, IACUC, of the University of Florida.
After each experiment, the animals were not used for other tests for a period of at 
least  five  days  in  order  to  give  them time  to  recover  from  bloodloss  and  as  a 
sufficient washout period.
2.1.1. Overnight Fasting
As described by E. J. Verspohl, blood glucose measurements can be carried out with 
either fasted or non-fasted animals. Either method has its advantages: fasted animals 
show a small fluctuation of blood glucose levels in a controlled setting, whereas non-
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fasted rats offer a more physiological situation (Verspohl, 2002).
To determine eventual advantages of either method, both models were tested. The 
animals  had  access  to  water  and  food  pellets  ad  libidum.  Food  deprivation  was 
implemented for about 15 hours prior to the experiment.
2.1.2. Procedure for Oral Gavage
Figure 13.  Oral gavage – seizing all loose skin in the neck area
        (Source: www.scielo.br/img/revistas/rhc/v59n5//a06fig01.gif )
Figure 14.  The slightly curved gavage reaches down to the stomach
        (Source: www.urmc.rochester.edu/ucar/images/2fig7.gif )
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For this, a stainless steel ball tipped gavage and a 3ml syringe were used. Following 
the guidelines of AALAS Learning Library for Animal Care and Use in Research 
and Education (www.aalaslearninglibrary.org), slightly curved needles were used.
The animal needs to be held firmly at the neck area, seizing all loose skin (see figure 
13). This ensures that the procedure can be performed quickly and without harm to 
the animal. In this position, the mouth of the rat is already slightly opened and the 
gavage can be inserted. Moving the gavage forward from the side and behind the 
back teeth, it can now slide down the oesophagus and into the stomach (see figure 
14) without pressure, on its own accord. 
2.1.3. Basal glucose measurement
Male Wistar rats weighing 300 – 350 g were purchased from Harlan (Indianapolis, 
IN, U.S.A.). Rats were housed in cages of two at 20 ± 1 °C in a 12-h light/dark cycle. 
Tap water  and  food  pellets  were  available  ad  libidum.  Groups  of  six  rats  were 
randomly assigned to different treatment groups. All experiments were carried out in 
a quiet room between 8:00 a.m. and 1:00 p.m. 
The second set  of rats  were white Sprague Dawley rats from Harlan, see above, 
purchased at around nine weeks of age and used for a period of around nine weeks. 
After  overnight  food  deprivation,  control,  glyburide  (18mg/kg),  sitagliptin 
(100mg/kg) and four different doses of the extract (1.5mg/kg, 6.0mg/kg, 30.0mg/kg 
and  60.0mg/kg)  were  given  orally  immediately  after  the  first  blood  collection, 
equalling timepoint zero. 
For the second set of rats, overnight fasting was not implemented.
Blood samples from the sublingual veins were collected  into heparinized capillary 
tubes at  timepoints  0,  30,  60,  120  and  180  min.  Blood  glucose  was  measured 
immediately  after  the  puncturing  of  the  vein,  using  a  commercially  available 
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glucometer.
After every blood collection, approximately 0.9 ml isotonic saline was administered 
i.p. (see below for further details)
2.1.4. Glucose Tolerance Test (GTT)
Herbal extracts in concentrations as described above were orally administered 30 
minutes prior to the first blood collection. In order to increase plasma glucose levels, 
rats  were  challenged  by  glucose  (2g/kg)  i.p.  immediateley  after  the  first  blood 
collection (timepoint 0). Additional blood samples were collected at 15, 30, 60 and 
120  min.  The  subsequent  procedure  was  the  same as  described  above  for  basal 
glucose measurement.
2.1.5. Blood collection
Blood collection from the  vena sublingualis requires anesthesiation of the animal. 
For this, the rats were placed in a desiccator that had been prepared with about 3 to 4 
ml of isoflurane (halothane respectively) and layers of absorbent paper. When the air 
in the desiccator was saturated, the rat was placed in it until breathing and heartbeat 
slowed down (after about two minutes).
Blood was now collected from the sublingual vein following the procedure described 
by Zeller et al. (Zeller et al., 1998).
Blood was  withdrawn by puncturing the  Vena sublingualis at  intervals  indicated 
above. The vein is to be punctured by holding the needle parallel to the vein so as not 
to  pierce  through  the  vessel.  The  vein  can  be  ruptured  carefully  to  assure  that 
enough  blood  can  be  collected.  Both  venae can  be  punctured  alternately. 
Approximately 400µl blood were collected / animal / sampling time by holding the 
                                                                                                                                                    
40
Chapter 5 – Materials and Methods
__________________________________________________________________________
rat with the head downwards and applying gentle pressure to the neck area to ease 
bloodflow (see Figure 13). 
Blood samples were collected in special tubes with a heparin layer to avoid clotting. 
The tubes were kept on ice until the blood was centrifuged for serum seperation. The 
samples were centrifuged at 4°C at 2800 rpm for 15 minutes.
Plasma was then pipetted into Eppendorff caps and stored at -20°C for subsequent 
measurement of insulin and DPPIV levels. 
Figure 15. Blood collection.
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2.1.6. Volume replacement after blood collection
In order to replace the approxiamately 400µl blood collected at each timepoint, about 
0,9ml isotonic saline was administered i.p., using a 23 gauge ¾ needle.
2.2. Insulin ELISA
Enzyme Linked Immunosorbent Assays can be classified in six categories: indirect, 
direct competitive, antibody-sandwich, double antibody-sandwich, direct cellular and 
indirect cellular. 
Figure 16: ELISA test-principle
        (Source: http://biosystemdevelopment.com)
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The antibody-sandwich ELISA may be the most useful assay for antigen-detection, 
as it generally is between 2 and 5 times more sensitive than those in which antigen is 
directly bound to the solid phase (Hornbeck et al., 2000).
For detection of insulin, a solid phase sandwich ELISA was purchased from ALPCO 
Diagnostics  (Insulin  (Rat)  Ultrasensitive  EIA,  Cataologue  Nr.:  80-INSTRU-E01, 
Salem, New Hampshire, USA).
The 96 well microplate is coated with an insulin-specific (capture) antibody. After 
insulin  standards,  mammalian  insulin  controls  and  samples  are  added  to  the 
microplate, the plate is incubated with horseradish peroxidase enzyme (monoclonal 
antibody).  Unbound  antigen  is  washed  out,  and  substrate  is  added,  followed  by 
another incubation period. After the stop solution has been added, the optical density 
is measured by a spectophotometer at 450 nm. The degree to which substrate has 
been hydrolized corresponds proportionally to the amount of antigen in the samples 
([Hornbeck et al., 2000], [Alpco Diagnostics]).
2.3. DPPIV Assay
For the detection of DPPIV in rat serum, a protease assay was carried through. The 
following chemicals were purchased from Sigma-Aldrich, St. Louis, Missouri, USA: 
Trizma® base, dipeptidyl peptidase IV recombinant human, 4-nitroaniline and gly-
pro-p-nitroaniline.
DPPIV  is  a  serine  protease  that  cleaves  proteins  after  proline  residues.  The 
luminogenic substrate contains a Gly-Pro sequence that  is cleaved by the DPPIV 
enzyme.  The  ensuing  luciferase  aminoluciferin  is  oxidized  during  the  luciferase 
reaction, resulting in the production of light (see Figure 17). 
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The following substances were used for the assay:
A. 0.1 M Tris-HCl, pH 8.0 at 37°C
B. 1mM gly-pro-p-nitroaniline solution Sigma
C. 1 mM p-nitroaniline solution (pNA)
D. Dipeptidyl peptidase enzyme solution
In a 96-well plate, standards were pipetted: 0, 20, 40, 60, 80 and 100µl of pNA were 
filled up to 0.1 ml with reagent A. Enzyme samples were pipetted at 10, 20, 30, 40 
and 50 µl and filled up to 0.1 ml with reagent A as well. Correspondingly, 60µl of rat 
plasma samples were pipetted in the remaining wells and filled up to 0.1 ml with 
reagent A. 0.1ml of reagent B was now added to each well, starting the reaction. 
After  15  minutes  of  incubation  at  37°C,  absorbance  was  read  at  560  nm  in  a 
microplate reader. 
Figure 17. DPPIV immuno assay test principle
       (Source: www.promega.com)
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2.4. Analysis
Data are presented as mean ± SEM for each group (N = 6). Significant differences 
among the groups were determined by two-way analysis of variance (ANOVA). The 
significance of  the  difference between the means of  test  and control  studies  was 
established by Bonferroni post-hoc test. P values of less than 0.05 were considered 
significant. Outliers were calculated using GraphPads online Grubbs test calculator 
on www.graphpad.com/quickcalcs/Grubbs1.cfm
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Chapter 6
Results
1. Influence of different anaesthetics on blood glucose levels
As it can be seen in figure 18, the blood glucose levels in unfasted male rats were 
slightly  higher  when  halothane  was  used  as  anaesthetic  than  with  isoflurane. 
Additionally, isoflurane shows a more linear increase in blood glucose levels than 
halothane, which accounts for the fact that depth of anaesthesia was easier to control 
with isoflurane. For detailed information concerning the necessity of this preliminary 
comparision, see chapter 7.
Isoflurane was therefore chosen for the subsequent testing of Artemisia dracunculus 
extracts.
Figure 18: Blood glucose levels in unfasted rats.
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2. Influence of food withdrawal on blood glucose levels
Figure 19 shows that fasting has no significant effect on blood glucose. While the 
rats had access to water ad libidum, food pellets were taken away for an overnight 
fasting period of about 15 hours.
Figure 19.  Fasted vs. unfasted rats.
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3. Differences in blood glucose of Wistar and Sprague Dawley rats
As can be seen in figure 20, the difference between basal blood glucose levels in 
Wistar and Sprague Dawley rats is not significant. While the discrepancy increases 
slightly in the glucose tolerance test (see figure 21), it still remains insignificant.
Figure 20. Wistar vs. Sprague Dawley rats, basal
                                                                                                                                                    
48
Chapter 6 – Results
__________________________________________________________________________
Figure 21. Wistar vs. Sprague Dawley rats, glucose tolerance test
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4. Dose finding study
In the basal dose finding study (see figure 22), the positive control glyburide proved 
to be the only significant compound. The significant effect could be observed from 
the second measurement at 30 minutes to the last at 180 minutes. The second positive 
control sitagliptin did not affect the blood glucose levels at all. 
In the glucose tolerance test, glyburide showed a significant effect at 15, 30 and 60 
minutes,  with  the  Artemisia  dracunculus extracts  of  30  and  60  mg/kg  being 
significant at 30 minutes. 
Figure 22. Dose finding study with Wistar rats. basal
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Figure 23. Dose finding study Artemisia dracunculus extracts with Wistar 
        rats, glucose tolerance test
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5. Plasma analysis – Insulin ELISA
As shown in figure 24, Glyburide increased insulin levels for the first 30 minutes 
after the treatment, while the Artemisia dracunculus extract exhibited some activity 
at 15 minutes.
Figure 24. ELISA insulin data from glucose tolerance test
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6. Plasma analysis – DPP-IV Assay
Although Sitagliptin did not achieve a significant decrease in blood glucose levels, it 
did show a severe decline in DPPIV values, while both extracts had no effect. 
Figure 25. DPPIV data from glucose tolerance test
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Chapter 7
Discussion
1. Anaesthetic
As initially  planned,  first  experiments  for  this  study  were  carried  out  using  the 
anaesthetic isoflurane, but regulations changed at this point and now prohibited the 
use of halothane within the United States of America. Isofluran was considered a 
possible  alternative.  Due  to  a  lack  of  data  on  the  comparability  of  the  two 
anaesthetics, is was deemed necessary to carry out tests to determine their impact on 
blood glucose levels in rats. 
Although a study by Kofke et al. (1987) has shown that the blood glucose levels in 
plasma and brain were significantly elevated in the isoflurane group compared to 
enflurane and halothane, it was found in the present study that blood glucose levels 
of the isoflurane group were slightly below those of the halothane group. This could 
result from the fact that the rats in Kofkes study were exposed to anaesthetics for a 
considerably longer time, being mechanically ventilated for  a  period of 60 to 75 
minutes, while the rats for the Artemisia-study were exposed to the anaesthetic five 
times for only about 2 minutes each, following the test setup as described for the 
basal glucose measurement (see above).
This outcome corresponds with a study on humans by Young et al. The effects of 
different anaesthetic techniques (isoflurane, halothane, fentanyl and sufentanil)  on 
plasma glucose levels were compared during cerebrovascular surgery. No significant 
difference between the  anaesthetics  could  be detected,  but  each group  showed a 
gradual increase in plasma glucose during the procedure (Young et al., 1990).
Additionally to the measurement of blood glucose levels, it could be observed that 
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the  anaesthesia  was  not  as  deep  with  isoflurane  as  with  halothane,  and  that 
consequently resuscication was more rarely necessary. The anaesthesia was easier to 
control and the animals were easier to handle with isoflurane.
Another advantage of isoflurane is the fact that it is less prone to lead to hepatotoxic 
side  effects than halothane.  An additional  interesting side  effect in  regard of  the 
present work is the fact that isoflurane dilates peripheral blood vessels which may 
facilitate blood collection from the vena sublingualis (Mutschler et al., 2001).
Summing up, isoflurane was more convenient to work with and it caused slightly less 
changes to glucose levels than halothane. 
2. Influence of food withdrawal on blood glucose levels
Concerning the access to food animals in a diabetes study have, two possibilities 
with different advantages exist as described by Verspohl (2002) and has already been 
mentioned (see chapter 3 'Materials and Methods'). As no data could be found on the 
actual effect food deprivation has on blood glucose levels, this experiment had to be 
conducted in order to find the method best suitable for the present study, but also 
with  regard to  animal wellfare  and comparability  of  data that  have already been 
published in various papers.
Ensuing  data  shows  clearly  that  figures  differ  only  slightly,  which  suggests  a 
comparability of both approaches. In order to reduce stress and discomfort for the 
laboratory animals, it is advisable to provide food at libidum. It has to be noted that, 
although  food  was  not  taken  away  from  the  unfasted  animals  before  the  blood 
collection, it could be observed that the rats in most cases did not eat after they were 
brought in the animal procedure room.
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3. Dose Finding Study
Artemisia dracunculus extracts (as well as sitagliptin) did not influence basal glucose 
levels.  In  the  glucose  tolerance  test,  extracts  at  concentrations  of  30mg/kg  and 
60mg/kg significantly decreased blood glucose levels after 15 minutes. The dose of 
60mg/kg was chosen for testing of plasma samples due to the fact that the whole 
curve  had  slightly  lower  glucose  levels.  As  well,  additional  data  confirmed  the 
hypothesis that the antidiabetic potency of concentration 60mg/kg is higher than that 
of 30mg/kg.     
4. Plasma analysis – Insulin ELISA and DPP-IV assay
While  Glyburide  showed  an  increased  insulin  secretion,  the  Artemisia extract 
containing 60mg/kg caused no augmentation in plasma insulin with levels beeing 
even below those of the control group. The graph for concentration 6mg/kg however 
showed an increase of plasma insulin at 15 minutes, followed by a sharp decline in 
insulin levels. 
In the DPPIV assay, only Sitagliptin effectively lowered DPPIV levels, while neither 
Artemisia  dracunculus extract  affected plasma DPPIV concentrations.  While  this 
suggests a mechansim of action other than the inhibition of DPPIV, additional testing 
in this direction would be interesting.
Insulin ELISA and DPPIV assay were completed in order to compare the activity of 
the extracts to the positive control and to assess timepoints of activity.
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5. Outlook
What sets the present work apart from previously published literature concerned with 
possible antidiabetic effects of Artemisia dracunculus L. extracts are two important 
points: firstly, the fact that most studies, such as Ribnicky et al., 2006, Wang et al., 
2008,  Govorko  et  al.,  2007 and various others,  worked with an ethanolic extract 
which,  though  potentially  more  active  than  the  aqueous  extract,  is  also  more 
problematic  due  to  its  potentially  cancerogenic  and  hepatotoxic  compounds 
methyleugenol and estragol (as discussed previously). Bearing in mind the possible 
use of this extract as an antdiabetic drug or functional food, it seems important to 
explore the possibilities of the aqueous extract more profoundly. 
The second difference is the concentration of the herbal extract. The present study 
investigated  the  effect  of  extract  concentrations  ranging from 1.5  mg/kg  to  60.0 
mg/kg,  which are more feasible  in regard to  possible human consumption as  for 
example a dosage of 500 mg/kg as used by Ribnicky et al., 2006 and 2009. 
In this study, non-diabetic rats have been used to determine the effects of Artemisia 
dracunculus extracts on blood glucose, plasma insulin and DPPIV levels. It should 
also be noted that a recent diabetes study on the effects of an alcoholic extract of A. 
dracunculus L. on diabetic and non-diabetic mice found that both glucose and insulin 
concentrations did change significantly  only in diabetic  animals (Ribnicky  et  al., 
2006).
Looking at extrapancreatic effects and the mechanism of action with  in vitro tests 
should yield interesting data as well. 
To optimize antidiabetic  potency of  the  extract,  the  effect  of  different extraction 
methods  and  possible  additives  such  as  the  bioenhancer  Labrasol  could  be 
investigated. 
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5.1. Functional Foods
As mentioned earlier, the incidence of diabetes is increasing worldwide, but still no 
treatment  has  been  found  and  the  current  approach  of  oral  antidiabetic  agents 
combined with exercise and a healthy diet does not seem to be an adequate response 
to  the  diabetes  epidemic.  In  this  regard,  the  screening  of  new compounds  is  of 
eminent importance and emphasis should be laid on the evaluation of plant extracts, 
as this field has long been neglected by diabetes research (Verspohl, 2002). 
Plant extracts as dietary supplements that can help patients control hyperglycemia 
could prove highly beneficial.  Extracts of  Artemisia dracunculus L. have already 
been examined regarding their possible use as dietary supplements (Ribnicky et al., 
2006).
As there is still no cure for diabetes, intervention in the prediabetic stage in order to 
prevent  a  progression of  the  disease  seems a  reasonable approach (The Diabetes 
Prevention Program, 1999). Several approaches could be used to achieve this: while 
lifestyle modifications are difficult to maintain, drug therapies may prove detrimental 
to the large number of individuals who may never develop type 2 diabetes mellitus 
(Rosenstock, 2007). Whether dietary supplents could be of use in this field, either in 
intensifying the effect of lifestyle modification or in addition to drug therapies has 
yet to be studied. But regarding the fact that the increasing diabetes prevalence is 
strongly linked to and preceded by a worldwide obesity epidemic ([Reimann et al., 
2009],  [Bray, 1998],  [Stumvoll  et  al.,  2005]),  an  individual  and  more  targeted 
combination of these remedies to reduce impaired glucose tolerance and impaired 
fasting glucose (see chapter 1) at an early stage could prove to be succesfull. A long-
term goal would be to develop a remedy that targets specific pathologic defects, thus 
restoring normoglycaemia (Stumvoll et al., 2005).
But which requirements have to be met for a food to be called functional? According 
to Diplock et al., the following working definition can be adopted:
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„A food can be regarded as 'functional' if it is satisfactorily demonstrated to affect  
beneficially one or more target functions in the body, beyond adequate nutritional 
effects, in a way that is relevant to either an improved state of health and well-being  
and/or reduction of risk of disease.“ (Diplock et al., 1999) 
Until  now, evidence  supporting  the  functionality  of  foods  for  the  prevention  of 
overweight and diabetes is, however, incomplete (Riccardi et al., 2005). Studies such 
as  the  Finnish  Diabetes  Prevention  Study  (Tuomilehto  et  al.,  2001)  show  that 
moderate weight loss of about 5% can decrease the development of T2DM by half in 
individuals at risk for this disease. This shows the tremendous potential that lies in 
functional foods targeted at this indication (Hill et al., 2002).
Developing functional foods also accounts for the trend in modern society: the use of 
complementary and alternative medicine is rising, with herbal medicine being most 
popular ([Tindle et al., 2005], [Klein et al., 2004]).
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